Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Over decades, researchers have focused on the epigenetic control of DNA-templated
processes. Histone modification, DNA methylation, chromatin remodeling, RNA modification …

Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we
characterized early kinetics in tumor-infiltrating and circulating immune cells in oral cancer …

Abstract N 6-methyladenosine (m6A) is the most abundant epigenetic modification of RNA,
and its dysregulation drives aberrant transcription and translation programs that promote …

Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrated, but the effect of
immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here …

Tissue resident memory CD8+ T (TRM) cells offer rapid and long-term protection at sites of
reinfection. Tumour-infiltrating lymphocytes with characteristics of TRM cells maintain …

The efficacy of adoptive T-cell therapies largely depends on the generation of T-cell
populations that provide rapid effector function and long-term protective immunity. Yet it is …

T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …